| __timestamp | BioMarin Pharmaceutical Inc. | Regeneron Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 461543000 | 1271353000 |
| Thursday, January 1, 2015 | 634806000 | 1620577000 |
| Friday, January 1, 2016 | 661905000 | 2052295000 |
| Sunday, January 1, 2017 | 610753000 | 2075142000 |
| Monday, January 1, 2018 | 696328000 | 2186100000 |
| Tuesday, January 1, 2019 | 715007000 | 3036600000 |
| Wednesday, January 1, 2020 | 628116000 | 2735000000 |
| Friday, January 1, 2021 | 628793000 | 2908100000 |
| Saturday, January 1, 2022 | 649606000 | 3592500000 |
| Sunday, January 1, 2023 | 746773000 | 4439000000 |
| Monday, January 1, 2024 | 747184000 | 5132000000 |
Igniting the spark of knowledge
In the competitive world of pharmaceuticals, innovation is key to staying ahead. Over the past decade, Regeneron Pharmaceuticals, Inc. and BioMarin Pharmaceutical Inc. have demonstrated their commitment to research and development (R&D) with significant investments. From 2014 to 2023, Regeneron consistently outspent BioMarin, with R&D expenses peaking at approximately $4.4 billion in 2023, a staggering 250% increase from 2014. In contrast, BioMarin's R&D spending grew by about 62% over the same period, reaching nearly $747 million in 2023.
This trend highlights Regeneron's aggressive strategy in prioritizing innovation, potentially leading to groundbreaking treatments and therapies. Meanwhile, BioMarin's steady investment reflects a more conservative approach, focusing on sustainable growth. As the pharmaceutical landscape evolves, these spending patterns may influence each company's market position and ability to bring new products to market.
Research and Development Expenses Breakdown: Regeneron Pharmaceuticals, Inc. vs Blueprint Medicines Corporation
R&D Spending Showdown: Regeneron Pharmaceuticals, Inc. vs Bio-Techne Corporation
Research and Development Investment: Regeneron Pharmaceuticals, Inc. vs Pharming Group N.V.
Analyzing R&D Budgets: Regeneron Pharmaceuticals, Inc. vs Ultragenyx Pharmaceutical Inc.
Analyzing R&D Budgets: Regeneron Pharmaceuticals, Inc. vs Veracyte, Inc.
Regeneron Pharmaceuticals, Inc. vs Agios Pharmaceuticals, Inc.: Strategic Focus on R&D Spending
Who Prioritizes Innovation? R&D Spending Compared for Regeneron Pharmaceuticals, Inc. and MannKind Corporation
Who Prioritizes Innovation? R&D Spending Compared for Regeneron Pharmaceuticals, Inc. and Supernus Pharmaceuticals, Inc.
Research and Development: Comparing Key Metrics for Biogen Inc. and BioMarin Pharmaceutical Inc.
Viatris Inc. or BioMarin Pharmaceutical Inc.: Who Invests More in Innovation?
Analyzing R&D Budgets: BioMarin Pharmaceutical Inc. vs Vericel Corporation
R&D Insights: How BioMarin Pharmaceutical Inc. and Novavax, Inc. Allocate Funds